

Marina F Caskey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8008077/marina-f-caskey-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86
papers

10,381
citations

43
h-index

101
g-index

103
ext. papers

14,906
ext. citations

24.7
avg, IF

6.36
L-index

#	Paper	IF	Citations
86	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5	1
85	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. <i>Lancet Microbe, The</i> , 2022 , 3, e203-e214	22.2	2
84	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. 2022 ,		1
83	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022 ,		3
82	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.. <i>Trials</i> , 2022 , 23, 263	2.8	0
81	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , 2022 ,	32.3	10
80	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022 ,	50.4	14
79	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	93
78	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. 2021 ,		31
77	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021 ,	50.5	16
76	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021 ,	50.4	69
75	Evolution of Antibody Immunity to SARS-CoV-2 2021 ,		43
74	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021 , 65, 103252	8.8	5
73	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021 ,		24
72	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies 2021 ,		27
71	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. <i>Clinical Chemistry</i> , 2021 , 67, 1249-1258	5.5	5
70	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021 ,		19

69	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021 , 595, 426-431	50.4	247
68	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021 , 12, 4196	17.4	106
67	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	178
66	Behavioral and social science research to support development of educational materials for clinical trials of broadly neutralizing antibodies for HIV treatment and prevention. <i>Clinical Trials</i> , 2021 , 18, 17-27 ²⁻²		3
65	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021 , 591, 639-644	50.4	652
64	Persistent cellular immunity to SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	59
63	TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability 2021 ,		2
62	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021 , 592, 616-622	50.4	730
61	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York 2021 ,		54
60	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021 , 95,	6.6	11
59	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021 , 12, 4886	17.4	30
58	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021 , 54, 1853-1868.e7	32.3	83
57	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021 ,	50.4	65
56	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021 ,		54
55	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
54	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2	485
53	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. <i>Cell Host and Microbe</i> , 2020 , 28, 335-349.e6	23.4	25
52	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020 , 9,	8.9	784

51	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. <i>Nature Medicine</i> , 2020 , 26, 222-227	50.5	50
50	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 2020 ,		60
49	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 2020 ,		30
48	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses 2020 ,		35
47	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro 2020 ,		15
46	Persistent Cellular Immunity to SARS-CoV-2 Infection 2020 ,		9
45	Broadly neutralizing antibodies for the treatment and prevention of HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2020 , 15, 49-55	4.2	17
44	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. <i>Cell Reports Medicine</i> , 2020 , 1, 100123	18	46
43	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020 , 584, 437-442	50.4	1167
42	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. <i>Antibodies</i> , 2020 , 9,	7	3
41	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	289
40	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	34
39	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020 , 26, 1339-1350	50.5	43
38	Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. <i>Journal of Virology</i> , 2020 ,	6.6	11
37	Delivery of anti-HIV bNAbs by viral vectors. <i>Lancet HIV,the</i> , 2019 , 6, e207-e208	7.8	4
36	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. <i>Lancet HIV,the</i> , 2019 , 6, e259-e268	7.8	87
35	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. <i>Nature Medicine</i> , 2019 , 25, 547-553	50.5	126
34	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019 , 14, e0219142	3.7	33

33	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2253-2264	16.6	42
32	Clonal CD4 T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. <i>Nature Medicine</i> , 2018 , 24, 604-609	50.5	72
31	Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 366-373	4.2	47
30	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2311-2324	16.6	55
29	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018 , 92,	6.6	32
28	Relationship between intact HIV-1 proviruses in circulating CD4 T cells and rebound viruses emerging during treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E11341-E11348	11.5	42
27	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018 , 561, 479-484	50.4	250
26	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018 , 24, 1701-1707	50.5	142
25	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017 , 23, 185-191	50.5	282
24	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. <i>Cell</i> , 2017 , 169, 597-609.e1199	50.2	1199
23	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7908-E7916	11.5	117
22	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. <i>New England Journal of Medicine</i> , 2016 , 375, 2019-2021	59.2	55
21	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016 , 535, 556-60	50.4	298
20	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016 , 352, 997-1001	33.3	202
19	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. <i>Science</i> , 2016 , 352, 1001-4	33.3	240
18	Circulating precursors of human CD1c+ and CD141+ dendritic cells. <i>Journal of Experimental Medicine</i> , 2015 , 212, 401-13	16.6	154
17	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015 , 522, 487-91	50.4	509
16	HIV-1 integration landscape during latent and active infection. <i>Cell</i> , 2015 , 160, 420-32	56.2	289

15	A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 140-7	3.1	56
14	A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers. <i>Blood</i> , 2012 , 120, 4124-4124	2.2	
13	Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. <i>Journal of Clinical Virology</i> , 2011 , 51, 54-8	14.5	35
12	In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. <i>PLoS ONE</i> , 2011 , 6, e19252	3.7	140
11	Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2357-66	16.6	219
10	Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 BXC candidate vaccine. <i>PLoS ONE</i> , 2010 , 5, e8816	3.7	45
9	Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1589-602	16.6	471
8	The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 2574-9	11.5	247
7	Clinical manifestations associated with HTLV type I infection: a cross-sectional study. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 365-71	1.6	58
6	Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 1499-504	1.6	41
5	Analysis of HIV-1 latent reservoir and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117		1
4	Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir		3
3	Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates		2
2	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
1	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7